Patrick McGuire, MD
Internal Medicine · Moss Point, MSNPI 1801809124
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $368 and has fallen 61.0% since, to $143 in 2025.
Across 76 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$250
- AstraZeneca$224
- Lilly USA, LLC$214
- Genentech USA, Inc.$93
- Biohaven Pharmaceutical Holding Company Ltd.$60
- AbbVie$60
- plus $318 from 12 others
What the payments were for
- Food & beverage$1,219100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $250 |
| AstraZeneca | 15 | $224 |
| Lilly USA, LLC | 13 | $214 |
| Genentech USA, Inc. | 6 | $93 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $60 |
| AbbVie | 4 | $60 |
| Exact Sciences | 3 | $51 |
| Baxter Healthcare | 1 | $39 |
| Pfizer | 2 | $39 |
| Renalytix AI, Inc. | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $30 |
| Bausch Health US, LLC | 2 | $26 |
| Zyla Life Sciences, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| GSK | 1 | $17 |
| Biofire Diagnostics, LLC | 1 | $15 |
| Boston Scientific | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$1,219 in reported general payments places this provider in the 65th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefdinir | 111 | $1,557 |
| Doxycycline Hyclate | 161 | $1,033 |
| Azithromycin | 208 | $765 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $298 |
| Mupirocin | 34 | $297 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 29 | $278 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 57 | $271 |
| Amoxicillin | 69 | $269 |
| Clindamycin Hcl | 16 | $203 |
| Fluticasone Propionate | 21 | $185 |
| Methocarbamol | 27 | $120 |
| Fluconazole | 21 | $94 |
| Prednisone | 57 | $90 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $88 |
| Diclofenac Sodium | 19 | $71 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Moss Point
- Kelly WilkinsonJackson$79K
- Shanna PettieJackson$53K
- Gabriel HernandezJackson$41K
- Indira VeerisettyRidgeland$25K
- James BridgesMadison$23K
- Brendan RossJackson$19K
- Hassan CheemaJackson$16K
- Jeffrey DennisOxford$15K
- Charles HillOxford$15K
- Paul VolanskyCorinth$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.